Open Orphan (ORPH) Exercise of Warrants and Issue of Shares September 23, 2019 – Posted in: Open Orphan (ORPH)

Open Orphan, a European-focussed, rare and orphan drug consulting services platform, announces that the Company has received notices of exercise of warrants over 539,654 ordinary shares of 0.1 pence each in the capital of the Company (“Ordinary Shares”) at a price of 0.1 pence per share for 191,051 ordinary shares and at a price of 2.2 pence per share for 348,603 ordinary shares. The gross proceeds of this exercise received by the Company amounts to…

Cathal Friel, CEO of Open Orphan (ORPH) discusses the appointment of David Kelly as an Independent Non-Executive Director on the Vox Podcast August 1, 2019 – Posted in: Open Orphan (ORPH)

Cathal Friel, Chief Executive Officer of Open Orphan (ORPH) talks about the appointment to the board of David Kelly as an Independent Non-Executive Director. Open Orphan plc is a European-focussed, rare and orphan drug consulting services platform. The Company consists of four elements: a European clinical research organisation and consultancy; an orphan drug services business; a Virtual Rep and Data Access Platform consisting of physicians and key opinion leaders; and a Health Data Platform to…

Open Orphan Plc (ORPH) Directorate Changes – Posted in: Open Orphan (ORPH)

Open Orphan, a European-focussed, rare and orphan drug consulting services platform, is pleased to announce the appointment to the board of David Kelly as an Independent Non-Executive Director. David has extensive orphan drug company experience both in Europe and in the USA. He was Executive Vice President and Managing Director of Ireland at Horizon Therapeutics plc, a biopharmaceutical company listed on Nasdaq and headquartered in Dublin. David has an excellent combination of experience having worked…

Open Orphan (ORPH) Chief Executive Officer, Cathal Friel discuss an operational update on the Vox Markets Podcast with Justin Waite July 15, 2019 – Posted in: Open Orphan (ORPH)

Click here to listen to the interview Open Orphan plc is a European-focussed, rare and orphan drug consulting services platform. The Company consists of four elements: a European clinical research organisation and consultancy; an orphan drug services business; a Virtual Rep and Data Access Platform consisting of physicians and key opinion leaders; and a Health Data Platform to partner with Patient Advocacy Groups. The Company is targeting rapid growth in one of the fastest growing…

Open Orphan (ORPH) sells its remaining shareholding in Integumen plc July 12, 2019 – Posted in: Open Orphan (ORPH)

Open Orphan, a European-focussed, rare and orphan drug consulting services platform, announces that it has now sold its remaining shareholding in Integumen plc following its disposal of 30,071,428 ordinary shares. The total proceeds of the sale are £566,846. This completes the process begun with the divestment of Innovenn UK limited to Integumen plc in November 2016. The disposal allows the Company to focus all its resources on its core strategy of creating a focused orphan drug platform…

Open Orphan (ORPH) Exercise of Warrants and Issue of Shares September 23, 2019 – Posted in: Open Orphan (ORPH)

Cathal Friel, CEO of Open Orphan (ORPH) discusses the appointment of David Kelly as an Independent Non-Executive Director on the Vox Podcast August 1, 2019 – Posted in: Open Orphan (ORPH)

Open Orphan Plc (ORPH) Directorate Changes – Posted in: Open Orphan (ORPH)

Open Orphan (ORPH) Chief Executive Officer, Cathal Friel discuss an operational update on the Vox Markets Podcast with Justin Waite July 15, 2019 – Posted in: Open Orphan (ORPH)

Open Orphan (ORPH) sells its remaining shareholding in Integumen plc July 12, 2019 – Posted in: Open Orphan (ORPH)

Address

Contact

Social

LEGAL